Literature DB >> 10462241

Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.

T R Jones1, N Obaldia, R A Gramzinski, Y Charoenvit, N Kolodny, S Kitov, H L Davis, A M Krieg, S L Hoffman.   

Abstract

Synthetic peptide and recombinant protein vaccines are optimally immunogenic when delivered with an effective adjuvant. Candidate vaccines currently insufficiently immunogenic may induce a protective immunity if they could be delivered with more effective adjuvants. For example, immunogens that induce promising responses when administered to mice with complete and incomplete Freund's adjuvants perform less well in primate animal models where complete Freund's adjuvant is not used. We report the use of synthetic oligodeoxynucleotides containing CpG motifs, the sequences of which are based on immunostimulatory bacterial DNA sequences, to enhance the immune response in Aotus monkeys to a synthetic peptide malaria vaccine. Monkeys were immunized with the synthetic peptide PADRE 45, a synthetic peptide containing amino acid sequences derived from the circumsporozoite protein (CSP) from Plasmodium falciparum, and delivered in an emulsion of saline and Montanide 720, a mannide oleate in oil solution, that also contained one of three oligodeoxynucleotides. The animals receiving oligodeoxynucleotides containing either three or four CpG motifs produced antibodies that bound a recombinant CSP as measured in ELISA, and reacted with P. falciparum sporozoites in a sporozoite immunofluorescent test. These responses were significantly greater than those seen in animals receiving the oligodeoxynucleotide without CpG motifs. These data indicate that oligodeoxynucleotides containing CpG motifs improve immunogenicity of peptide immunogens in non-human primates, and may be immunopotentiators useful in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462241     DOI: 10.1016/s0264-410x(99)00145-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

Review 1.  Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

Authors:  A M Krieg; A K Yi
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

4.  The use of CpG as an adjuvant to Toxoplasma gondii vaccination.

Authors:  Jennifer A Spencer; Bruce F Smith; Anthony J Guarino; Byron L Blagburn; Henry J Baker
Journal:  Parasitol Res       Date:  2004-01-15       Impact factor: 2.289

5.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice.

Authors:  Alberto Pinzon-Charry; Virginia McPhun; Vivian Kienzle; Chakrit Hirunpetcharat; Christian Engwerda; James McCarthy; Michael F Good
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

7.  Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.

Authors:  Barbara Flynn; Vivian Wang; David L Sacks; Robert A Seder; Daniela Verthelyi
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Authors:  Hang Xie; Ihsan Gursel; Bruce E Ivins; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

9.  Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.

Authors:  Karen A Near; Anthony W Stowers; Dragana Jankovic; David C Kaslow
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

10.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.